

## **Eden Biodesign Selected by Biotecno SA for cGMP Production of Cardiostrophin-1 for Treatment of Life Threatening Liver Diseases**

**Liverpool, UK, Research Triangle Park, N.C., USA and Oeiras, Portugal (October 13, 2009)** – Eden Biodesign, a globally-integrated provider of biopharmaceutical process development, cGMP manufacturing and consultancy services, today announced it has been selected by Biotecno SA to manufacture Cardiostrophin-1 for potential use in certain liver indications.

Eden Biodesign will generate the master cell bank and provide cGMP manufacture of drug substance for use in Phase I clinical trials. The manufacture of Cardiostrophin-1 will be undertaken in Eden Biodesign's cGMP manufacturing suites at its licensed facilities located in Liverpool, UK.

Crawford Brown, PhD, Chief Executive Officer, Eden Biodesign commented: "We are delighted to be able to add Biotecno to the wide range of established global pharmaceutical and biotechnology companies that have recognized Eden Biodesign's expertise and long experience in the development and cGMP production of biopharmaceuticals derived from all major production platforms. The contract signifies Eden Biodesign's continued strong growth in the marketplace and we are particularly pleased to be working on such an important product for treatment of serious hepatic conditions."

Biotechnol SA is a biotechnology company that develops biopharmaceutical products, and it has a special focus on the development of novel antibody-based therapeutics to treat life-threatening diseases such as cancer.

Together, Biotechnol and Digna Biotech are developing recombinant human CT-1 as a first-in-class drug to reduce ischemic reperfusion injury associated with organ transplantation and liver resection due to primary and secondary tumors, mainly originating from colorectal cancers. Both applications have a growing market with large unmet needs. CT-1 has already been granted Orphan Drug Status by the EMEA prevention of ischemia/reperfusion injury associated with solid organ transplantation; a similar application has been granted by the FDA.

“Cardiotrophin-1, is being developed for use in various applications in hepatology. This program is of strategic importance to both Biotechnol’s and Digna’s growth strategy. Biotechnol looked thoroughly across a wide competitive landscape considering a number of important criteria before we settled on Eden Biodesign,” said Dr. Philip Cunnah, Senior Director Process Development and Manufacturing, Biotechnol SA. “In Eden Biodesign we have found a competent manufacturing partner with the team and facilities, to implement the process developed at Biotechnol and manufacture Cardiotrophin 1 of an appropriate standard to support our clinical trials. We look forward to great results from working together and to expand this collaboration.”

Earlier this month, Biotechnol and Digna Biotech announced that they have entered into an Exclusive License and Option Agreement with Genentech, Inc. a wholly-owned member of the Roche Group, for developing and commercializing Cardiotrophin-1 for potential use in certain liver indications.

## **About Eden Biodesign**

Eden Biodesign is a globally-integrated biopharmaceutical company offering consultancy, biopharmaceutical design, process development and cGMP manufacturing services to leading biotech and pharmaceutical clients around the world. With a reputation for commercializing biopharmaceutical products and processes, the company offers expertise and guidance in multiple sectors. Eden Biodesign's world class facilities and knowledge in process development, manufacturing, regulatory and technology transfer support ensure that Eden Biodesign offers much more than a traditional CMO. Find out more at [www.edenbiodesign.com](http://www.edenbiodesign.com).

## **About BiotecnoI**

BiotecnoI is a biotechnology company developing biopharmaceutical products, and has a special focus on the development of novel antibody-based therapeutics to treat life threatening diseases such as cancer. BiotecnoI has a proprietary antibody format, which allows to develop multi-specific antibodies against various cancer targets. These formats are called Tribodies™. BiotecnoI is committed in building value by developing a diverse pipeline of antibody products to address unmet healthcare needs. BiotecnoI has a presence in the USA and carries its product development activities via its fully owned subsidiary BiotecnoI Pharmaceuticals Inc.

Through its facilities in Portugal, BiotecnoI leverages its business income by establishing in-house partner-led or collaborative programs, which provide BiotecnoI a strong client-based activity and an established track record. Find out more at [www.biotecnoI.com](http://www.biotecnoI.com)

###

**For more information, contact:**

**Eden Biodesign**

John D. Wagner

Propel Marketing Group

Tel. +001-919-796-9984

[Jdwagner@PropelMG.com](mailto:Jdwagner@PropelMG.com)

[www.PropelMG.com](http://www.PropelMG.com)

**Biotechnol**

Lagoas Park

Edifício 7, 1o Norte

2741-901 Oeiras

Portugal

Tel. +351-21-422-0520

[press@biotechnol.com](mailto:press@biotechnol.com)

[www.biotechnol.com](http://www.biotechnol.com)